🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Through our partnership with National Fish and Wildlife Foundation, we’re committed to restoring 100 km of riverside woodlands and planting more than 100K trees. Together, we can create a more sustainable future for people, society & the planet. We are #GenerationRestoration

At #EHA2024, we presented the full results from the ECHO Phase III trial in people with previously untreated #MantleCellLymphoma (#MCL). Read more here: bit.ly/4c1Kn3M #BloodCancer

Today, the U.S. FDA approved our IO-based therapy as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). Learn how this approval provides a new treatment option for patients here: bit.ly/3z2oXoT

Today we announced positive high-level results from our NIAGARA Phase III trial for muscle-invasive #BladderCancer (#MIBC), representing the first #immunotherapy regimen before and after surgery to extend survival in bladder cancer. Read more: bit.ly/3KYfUIg

We’re pleased to announce with Daiichi Sankyo US the U.S. FDA has accepted for review a supplemental Biologics License Application and granted Priority Review for our potential treatment for eligible patients with metastatic #breastcancer with certain levels of #HER2 expression.

To improve outcomes for people living with chronic respiratory diseases, we’re constantly pushing the boundaries of science to evolve our robust portfolio. Learn more about ways we’re revolutionizing care: spr.ly/6019UtzgZ #CHEST2024

We're working to deeply understand ways long-term care management can improve outcomes for patients with chronic kidney disease, heart failure and their comorbidities including hyperkalemia (HK). Learn more about effectively managing HK: bit.ly/4eNwrMl #ASN2024

For people living with chronic respiratory diseases such as asthma, everyday tasks can feel challenging. Learn more about ways we’re working to evolve our pipeline and improve care for these vulnerable patients: bit.ly/3UlKznQ #ACAAI

We’re working to create healthier, longer futures for people living with cardiovascular, renal and metabolic diseases such as hypertension (HTN). Learn more about the drivers of HTN and ways to improve outcomes: spr.ly/6010sTJwY #AHA2024

In collaboration with Daiichi Sankyo US, we announced the U.S. FDA granted a Breakthrough Therapy Designation for our potential treatment for adults with previously treated advanced EGFR-mutated non-small cell #lungcancer #NSCLC. spr.ly/6019QR4LV #AZUS

Today, in collaboration with Daiichi Sankyo US, we announced the U.S. FDA approval of our new treatment for adults with previously treated advanced HR-positive, HER2-negative #breastcancer. Learn more: spr.ly/6016acm3K #AZUS

Today, alongside Daiichi Sankyo US, we announced the U.S. FDA approval of a new indication for our therapy, now available for certain patients with previously treated metastatic #breastcancer. Learn more: spr.ly/6014xTItA #AZUS

Better understanding the risk factors for high blood pressure (hypertension) may help improve outcomes. A lesser-known driver is aldosterone dysregulation. Aldosterone is a hormone that helps regulate blood pressure. #HeartMonth spr.ly/6011Ih5KJ

The impacts of cardiovascular, renal and metabolic (CVRM) diseases on people continue to grow but may go under-recognized. We’re determined to demonstrate the impact of these diseases. Learn more: spr.ly/6011Ih5iz #HeartMonth

We’re targeting the root causes of inflammation in chronic respiratory diseases such as asthma, COPD and chronic rhinosinusitis with nasal polyps to transform care and patient outcomes. Learn more about our latest trial results in CRSwNP: spr.ly/6019LYNdf #AAAAI25

Millions of people in the U.S. have dyslipidemia. These patients are often left uncontrolled by statin-only treatments, which can lead to cardiovascular events. We’re developing therapies to shape the future of care. Learn more: spr.ly/6010FrqR4 #ACC25

Yesterday, we joined AstraZenecaUS to celebrate a $300 million investment in their new cell therapy facility in Montgomery County —bringing 150 high-skilled jobs & new hope in the fight against cancer. It was great to be joined by the entire District 15 team Senator

Today, with Daiichi Sankyo US, we announced high-level results from our DESTINY-Breast11 Phase III trial for HER2-positive early #breastcancer in the neoadjuvant setting. Learn more about the data and its potential impact for patients: spr.ly/6012NGojr #AZUS

Traditional approaches to asthma rescue may leave people with asthma at risk of exacerbations. Learn more about our latest data, published in NEJM: bit.ly/4koEotJ #ATS2025

Today, in collaboration with Daiichi Sankyo US we announced the U.S. FDA approval of our treatment for adults with previously treated locally advanced or metastatic EGFR-mutated non-small cell #lungcancer #NSCLC. Learn more: bit.ly/4kPwv12 #AZUS